CDMO Samsung Biologics Reports Continued Revenue Growth With Q3 Earnings

Samsung Biologics, one of the world’s largest contract development and manufacturing organizations (CDMOs) has released its 2022 third quarter earnings report, announcing that it’s reached a cumulative revenue surpassing KRW 2 trillion (approximately $1.4 billion) for the fiscal year. The CDMO recorded a consolidated revenue of KRW 873 billion, operating Read more